Berner K, Hernes E, Kvassheim M, Revheim ME, Bastiansen J, Selboe S, Bakken CL, Grønningsæter SR, Bruland ØS, Larsen RH, Bouzelmat L, Jardine VL, Stokke C (2025)
First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted ²¹²Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer
J Nucl Med, 66 (5), 732-738
DOI 10.2967/jnumed.124.269299, PubMed 40081958

Høyvik AJK, Kvassheim M, Ma LW, Wiig E, Hillestad T, Revheim ME, Liukaityte R, Bruland Ø, Juzeniene A (2025)
Therapeutic evaluation of [²¹²Pb]Pb-AB001 and [¹⁷⁷Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer
Eur J Nucl Med Mol Imaging (in press)
DOI 10.1007/s00259-025-07330-y, PubMed 40397137

Hompland I, Boye K, Wiedswang AM, Papakonstantinou A, Røsok B, Joensuu H, Bruland Ø (2024)
Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study
Acta Oncol, 63, 288-293
DOI 10.2340/1651-226X.2024.39851, PubMed 38712513